Navigation Links
Jan Gray Joins Resverlogix Board of Directors
Date:7/25/2008

TSX Exchange Symbol: RVX

CALGARY, July 25 /PRNewswire-FirstCall/ - Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) is pleased to announce effective immediately Jan Gray, CA has joined the Company's Board of Directors. On the subject of her appointment Jan Gray said, "Working with Resverlogix represents an exciting opportunity for me. The Company has done a wonderful job moving forward its lead drug into clinical trials. I expect the next foreseeable future to be both busy and very exciting. I am delighted to be joining the Board of Resverlogix."

"Jan's background as a chartered accountant adds a new skill set to the current Board of Directors, which is fundamental to the operation of the group in today's complex financial reporting environment. We are very pleased that she has agreed to join Resverlogix's Board," stated Donald McCaffrey, President and CEO of Resverlogix. "Jan brings to us a wealth of strategic and organizational excellence. In addition to her duties as a Board member Jan will provide sound counsel to our audit committee."

Jan Gray, CA is a practicing chartered accountant who specializes in advising high net worth individuals with complex financial, investment and taxation issues. She is also Executive Vice-President and Treasurer of Cartwright Canada Inc., a legal publishing company and Controller of Felesky Flynn LLP, a regional Alberta law firm. Ms. Gray's prior experience includes being a former Vice President and Controller of GE Capital Canada and previous to this she worked for Ernst & Young where she was a Manager in the National Accounting Group providing quality assurance on large public practice engagements.

Ms. Gray currently serves on the board of directors of GE Money Trust Company, a unit of General Electric Company and the Auxilium Foundation where she administers the multi-million dollar charitable fund. In addition Jan is a regular volunteer with Inn From the Cold, Calgary's only shelter for homeless families which allows the family to remain together.

About Resverlogix Corp.

Resverlogix Corp. is a leading biotechnology company engaged in the development of novel therapies for important global medical markets with significant unmet needs. The NexVas(TM) program is the Company's primary focus which is to develop novel small molecules that enhance ApoA-I. These vital therapies address the grievous burden of atherosclerosis and other important diseases such as acute coronary syndrome, diabetes, Alzheimer's disease and other vascular disorders. The Company's secondary focus is TGF-Beta Shield(TM), a program that aims to address burgeoning grievous diseases, such as cancer and fibrosis. Resverlogix Corp. trades on the Toronto Stock Exchange (TSX:RVX). For further information please visit http://www.resverlogix.com.

This news release may contain certain forward-looking statements that reflect the current views and/or expectations of Resverlogix Corp. with respect to its performance, business and future events. Such statements are subject to a number of risks, uncertainties and assumptions. Actual results and events may vary significantly. The TSX Exchange does not accept responsibility for the adequacy or accuracy of this news release.


'/>"/>
SOURCE Resverlogix Corp.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Roche Joins Forces With Enon Tabernacle Baptist Church to Provide Free Hepatitis C Testing to the Community
2. Ralf Rosskamp, M.D. Joins Biodels Scientific Advisory Board
3. Hank Plain Joins Morgenthaler Ventures as Partner
4. Legendary Earvin Magic Johnson Joins AFL/Signalife Cardiovascular Protection Team
5. Senior Research Analyst Richard Evans Joins AVOS Life Sciences
6. Dan Broderick Joins Prolog Ventures as Partner
7. Ingenuity Systems Joins Biomarkers Consortium
8. Founder of ILEX Oncology and Triton Biosciences, Richard Love, Joins Board of Directors of Cell Therapeutics, Inc. (CTI)
9. Glycominds Joins Biomolecular Photonic (BMP) Consortium to Develop New Molecular Imaging Technique
10. Progeniq Joins Microsoft in Bio IT Alliance
11. Jeffrey H. Buchalter Joins MacroGenics Board of Directors as Chairman
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... ... October 11, 2017 , ... Proscia Inc ., a ... Webinar titled, “Pathology is going digital. Is your lab ready?” with Dr. Nicolas ... practices and how Proscia improves lab economics and realizes an increase in diagnostic ...
(Date:10/11/2017)... LAGUNA HILLS, Calif. , Oct. 11, 2017 ... London (ICR) and University of ... prognostic tool to risk-stratify patients with multiple myeloma (MM), in ... nine . The University of Leeds ... by Myeloma UK, and ICR will perform the testing services ...
(Date:10/11/2017)... ... October 11, 2017 , ... ... and pregnancy rates in frozen and fresh in vitro fertilization (IVF) ... maternal age to IVF success. , After comparing the results from the fresh ...
(Date:10/10/2017)... ... October 10, 2017 , ... San Diego-based team building and cooking events company, ... today. The bold new look is part of a transformation to increase awareness, ... significant growth period. , It will also expand its service offering from its signature ...
Breaking Biology Technology:
(Date:4/3/2017)... 2017  Data captured by IsoCode, IsoPlexis ... a statistically significant association between the potency ... and objective response of cancer patients post-treatment. ... whether cancer patients will respond to CAR-T ... as to improve both pre-infusion potency testing and ...
(Date:3/29/2017)... the health IT company that operates the largest health ... today announced a Series B investment from BlueCross BlueShield ... investment and acquisition accelerates higi,s strategy to create the ... activities through the collection and workflow integration of ambient ... secures data today on behalf of over 36 million ...
(Date:3/24/2017)... Research and Markets has announced the addition of the ... Forecast to 2025" report to their offering. ... The Global Biometric Vehicle Access System ... over the next decade to reach approximately $1,580 million by 2025. ... forecasts for all the given segments on global as well as ...
Breaking Biology News(10 mins):